The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 17, 2016

Filed:

Dec. 15, 2011
Applicants:

Christoph Heusser, Oberwil, CH;

Julia Neugebauer, Munich, DE;

Eveline Schaadt, Munich, DE;

Stefanie Urlinger, Munich, DE;

Maximilian Woisetschlaeger, Perchtoldsdorf, AT;

Inventors:

Christoph Heusser, Oberwil, CH;

Julia Neugebauer, Munich, DE;

Eveline Schaadt, Munich, DE;

Stefanie Urlinger, Munich, DE;

Maximilian Woisetschlaeger, Perchtoldsdorf, AT;

Assignee:

Novartis AG, Basel, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.


Find Patent Forward Citations

Loading…